Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Jul 12, 2024 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – July 12, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the “Company”), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to...

Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762

Jul 8, 2024 | Press Releases

Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts–(Newsfile Corp. – July 8, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL®...

Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds

Jul 5, 2024 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – July 5, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more...

Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging

Jun 18, 2024 | Press Releases

Phio’s Compound RXI-185 is designed to slow progression of UV induced collagen breakdownMarlborough, Massachusetts–(Newsfile Corp. – June 18, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose...

Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio’s Lead Compound PH-762

May 28, 2024 | Press Releases

Intratumoral PH-762 has encouraging safety profile in the initial cohortEscalation to proceed to next dose concentrationMarlborough, Massachusetts–(Newsfile Corp. – May 28, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage...